Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to assesses the clinical efficacy of oral supplementation with glutamine over 3 years.

Clinical Trial Description

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder. The most common mutation is in the mtDNA gene MT-TL1 encoding the mitochondrial tRNALeu (UUR). For understanding the development of seizures in patients with mitochondrial disease, a study has recently emphasized the deficiency of astrocytic glutamine synthetase, creating a disinhibited neuronal network for seizure generation. The investigators propose to evaluate nine patients with mitochondrial DNA mutation and MELAS. Patients will receive oral supplementation with 12-18 g/day of glutamine (adjusted for weight and plasma concentrations). The primary outcome measures modification in clinical scales. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05255328
Study type	Interventional
Source	Hospital Universitario 12 de Octubre
Contact
Status	Active, not recruiting
Phase	N/A
Start date	July 1, 2021
Completion date	July 24, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01831934` - Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)	Phase 4
Not yet recruiting	`NCT06013397` - Effectiveness of Ketogenic Diet in MELAS Syndrome	N/A
Completed	`NCT04165239` - The KHENERGYZE Study	Phase 2
Completed	`NCT01603446` - L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome	Phase 2
Completed	`NCT00887562` - Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes	Phase 2
Active, not recruiting	`NCT00068913` - Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome	Phase 2
Completed	`NCT03888716` - A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease	Phase 1
Completed	`NCT04948138` - Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome	N/A
Completed	`NCT03056209` - Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers	Phase 1
Completed	`NCT01339494` - Nitric Oxide Production in MELAS Syndrome	Phase 0
Recruiting	`NCT02114554` - Mitochondrial nt3243 A>G Mutation in Taiwan	N/A
Recruiting	`NCT05554835` - Global Registry and Natural History Study for Mitochondrial Disorders
Completed	`NCT01252979` - Ketones & Mitochondrial Heteroplasmy	Phase 0
Completed	`NCT00004353` - Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia	N/A
Recruiting	`NCT03952234` - L-Citrulline Dose Finding Safety Study in MELAS	Phase 1